Filing Flows

Filing Flows › Arcus Biosciences (RCUS) › Next earnings date

Arcus Biosciences (RCUS) earnings: missed the estimate

Arcus Biosciences (RCUS) reported on Nov 4, 2026 and missed the EPS estimate: −$1.00 against −$0.89 (-12.0%). Revenue was $9.0M for Q3 2026, -65% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−12.0% vs estimate
Beat rate60%

The last report

Arcus Biosciences reported revenue of $9.0M for the third quarter 2026 (-65% Y/Y), net loss $128M: License and development services $8.0M, Other collaboration $1.0M. How it makes money → · Every quarter →

Arcus Biosciences: EPS against the estimate, last 5 reportsArcus Biosciences: EPS against the estimate, last 5 reportsEstimateReported−$1.29−$1.27Oct 25−$1.07−$0.89Feb 26−$0.83−$1.02May 26−$0.81−$0.72Aug 26−$0.89−$1.00Nov 26
Latest (Nov 26): Estimate −$0.89, Reported −$1.00.

Arcus Biosciences' latest quarter

Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Arcus Biosciences beat earnings?

Arcus Biosciences (RCUS) reported on Nov 4, 2026 and missed the EPS estimate: −$1.00 against −$0.89 (-12.0%).

When does RCUS report earnings?

The next date is not set yet.

Does Arcus Biosciences usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.